Clinical Commentary| Volume 138, ISSUE 2, P235-237, August 2015

Download started.


Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention


      • Early carcinomas/cancer precursor lesions identified in the fallopian tube of BRCA carriers are potential surrogate markers
      • Retrospective prevalence of these early events varies widely due to heterogeneity in the diagnostic methodology used
      • Cancer precursor lesions need to be defined with the rigorous validated procedures


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • George S.H.
        • Shaw P.
        BRCA and early events in the development of serous ovarian cancer.
        Front. Oncol. Jan 23 2014; 4: 5
        • Powell C.B.
        Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later.
        Gynecol. Oncol. Feb 2014; 132: 261-263
        • Tsoref D.
        • Panzarella T.
        • Oza A.
        Aspirin in prevention of ovarian cancer: are we at the tipping point?.
        J. Natl. Cancer Inst. Feb 2014; 106: djt453
        • Hennessy B.T.
        • Timms K.M.
        • Carey M.S.
        • et al.
        Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose).
        J. Clin. Oncol. Aug 1 2010; 28: 3570-3576
        • Garcia C.
        • Wendt J.
        • Lyon L.
        • et al.
        Risk management options elected by women after testing positive for a BRCA mutation.
        Gynecol. Oncol. Feb 2014; 132: 428-433
        • Gross A.L.
        • Kurman R.J.
        • Vang R.
        • Shih IeM
        • Visvanathan K.
        Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.
        J. Oncol. 2010; 2010: 126295
        • Finch A.
        • Shaw P.A.
        • Rosen B.
        • Murphy J.
        • Narod S.A.
        • Colgan T.J.
        Clinical and pathologic findings of prophylactic salpingo-oophorectomies 159 BRCA1 and BRCA2 carriers.
        Gynecol. Oncol. 2006; 100: 58-64
        • Powell C.B.
        • Kenley E.
        • Chen L.M.
        • et al.
        Risk reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
        J. Clin. Oncol. 2005; 23: 127-132
        • Callahan M.J.
        • Crum C.P.
        • Medeiros F.
        • et al.
        Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
        J. Clin. Oncol. 2007; 25: 3985-3990
        • Shaw P.A.
        • Rouzbahman M.
        • Pizer E.S.
        • Pintilie M.
        • Begley H.
        Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.
        Mod. Pathol. Sep 2009; 22: 1133-1138
        • Vicus D.
        • Shaw P.A.
        • Finch A.
        • et al.
        Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
        Gynecol. Oncol. Sep 2010; 118: 295-298
        • Semmel D.R.
        • Folkins A.K.
        • Hirsch M.S.
        • Nucci M.R.
        • Crum C.P.
        Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria.
        Mod. Pathol. Aug 2009; 22: 985-988
        • Medeiros F.
        • Muto M.G.
        • Lee Y.
        • et al.
        The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
        Am. J. Surg. Pathol. Feb 2006; 30: 230-236
        • Visvanathan K.
        • Vang R.
        • Shaw P.
        • et al.
        Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.
        Am. J. Surg. Pathol. Dec 2011; 35: 1766-1775
        • Vang R.
        • Visvanathan K.
        • Gross A.
        • et al.
        Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.
        Int. J. Gynecol. Pathol. May 2012; 31: 243-253